Beam Therapeutics (BEAM) Depreciation & Amortization (CF) (2019 - 2026)
Beam Therapeutics (BEAM) reported Depreciation & Amortization (CF) of $5.6 million for Q1 2026, up 1.39% year-over-year from $5.5 million in Q1 2025, and down 1.11% on a QoQ basis from $5.7 million in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $5.6 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 1.39% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.4 million (up 1.58% YoY) and the FY2025 annual result came in at $22.3 million, up 1.68% from the prior year.
- Depreciation & Amortization (CF) declined to $5.6 million in Q1 2026 per BEAM's latest filing, from $5.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $5.7 million in Q4 2025 and bottomed at $3.3 million in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $5.4 million (2024), against an average of $4.9 million.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) surged 136.91%; it then retreated 0.68% in 2025.
- Tracing BEAM's Depreciation & Amortization (CF) over 5 years: stood at $3.9 million in 2022, then soared by 35.95% to $5.4 million in 2023, then rose by 1.51% to $5.4 million in 2024, then advanced by 4.13% to $5.7 million in 2025, then declined by 1.11% to $5.6 million in 2026.
- Per Business Quant, the three latest BEAM Depreciation & Amortization (CF) figures stand at $5.6 million (Q1 2026), $5.7 million (Q4 2025), and $5.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | 5.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.61 Mn |
| Mar 31, 2026 | 5.61 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Jun 30, 2025 | 5.54 Mn |
| Mar 31, 2025 | 5.53 Mn |
| Mar 31, 2025 | 5.53 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.58 Mn |
| Jun 30, 2024 | 5.58 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Dec 31, 2023 | 5.36 Mn |
| Dec 31, 2023 | 5.36 Mn |
| Sep 30, 2023 | 5.19 Mn |
| Sep 30, 2023 | 5.19 Mn |
| Jun 30, 2023 | 4.82 Mn |
| Jun 30, 2023 | 4.82 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Mar 31, 2023 | 4.65 Mn |
| Dec 31, 2022 | 3.94 Mn |
| Dec 31, 2022 | 3.94 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Sep 30, 2022 | 3.47 Mn |
| Jun 30, 2022 | 3.42 Mn |
| Jun 30, 2022 | 3.42 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Dec 31, 2021 | 2.63 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Mar 31, 2021 | 1.40 Mn |
| Mar 31, 2021 | 1.40 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Dec 31, 2020 | 1.27 Mn |
| Sep 30, 2020 | 1.22 Mn |
| Sep 30, 2020 | 1.22 Mn |
| Jun 30, 2020 | 1.15 Mn |
| Jun 30, 2020 | 1.15 Mn |
| Mar 31, 2020 | 1.10 Mn |
| Mar 31, 2020 | 1.10 Mn |
| Dec 31, 2019 | 1.00 Mn |
| Dec 31, 2019 | 1.00 Mn |
| Sep 30, 2019 | 908,000.00 |
| Sep 30, 2019 | 908,000.00 |
| Jun 30, 2019 | 858,000.00 |
| Jun 30, 2019 | 858,000.00 |
| Mar 31, 2019 | 735,000.00 |
| Mar 31, 2019 | 735,000.00 |